Bernstein Liebhard LLP reports that 41 Attorneys General Support expansion of liability claims against generic drug manufacturers

New York, NY (PRWEB) 30 May 2012 Bernstein Liebhard LLP, a national law firm represents clients in Fosamax femur fracture lawsuits and other dangerou...

New York, NY (PRWEB) 30 May 2012

Bernstein Liebhard LLP, a national law firm represents clients in Fosamax femur fracture lawsuits and other dangerous drug litigation, reported that on 11 2012, the National Association of Attorneys General (NAAG) sent a letter to Senators Patrick J. Leahy and Al Franken in support of the proposed legislation for the consumers of generic drugs have the same protections that exist for consumers of brand-name drugs want to restore it. The 11th May 2012 letter, the state attorneys general has been signed by 41 countries, argues that consumers take their rules, be filled with the brand version of the drug by state law to be protected by inadequate warnings, but consumers whose pharmacists fill their prescriptions with the generic version of that protection will now be denied. The NAAG letter noted that the negative consequences of the fact that over 70% of prescriptions in the United States are filled with generic drugs increased.

Bernstein Liebhard LLP partner Felecia L. Stern commented, We are confident that Congress takes heed of the NAAG letter. One of the most difficult tasks that we take it to the branded products.’s Face tells potential customers that we help them because cant find their medical records that they have taken a generic form of the drug, This has come in the Fosamax lawsuits countless times, and we are faced with similar problems in other drug litigation.?

legislation would prevent dismissal of complaints from users, generic forms of drugs like Fosamax and Zithromax

Took Filed

present due to a recent Supreme Court decision, PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), have failed, according to the consumer, generic manufacturers to adequately warn them of dangerous side effects had their cases dismissed. According to the Supreme courts presented, are state laws that generic manufacturers to adequately warn consumers of dangerous side effects displaced because current federal law allows only brands independently change label warnings. The proposed law would repeal this decision.?

lawyers Bernstein Liebhard LLP are confident that Congress passes the Patient Safety and Generic Labeling Improvement Act (S.2295). Unfortunately, many people who have been injured as a result of taking the generic equivalent of drugs, such as Fosamax and Zithromax, very limited legal recourse. This new law would keep manufacturers of generic and brand-name drugs similarly accountable to consumers for not adequately warn of dangerous side effects. For example, would people who took alendronate or azithromycin be able to seek compensation for their injuries in the same manner as the filing Fosamax femur fracture lawsuits or Zithromax.

Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The company was established by The National Law Journal was the plaintiff Hot List, recognizing the top plaintiffs firms in the country, in the past nine consecutive years. Only two companies in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

(877) 779-1414

ATTORNEY ADVERTISING. ? 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016 (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Felecia L. Stern, Esq.

Bernstein Liebhard LLP

clear = “all”

Leave a Reply